- November 26, 2012 | BY
After the recent failures of two Alzheimer’s drugs that target amyloid beta plaques, many have questioned the approach. But new data released in October shows promise for the amyloid hypothesis, provided plaque-targeting drugs are applied early in the disease process.
- November 12, 2012 | BY
Although Alzheimer’s disease (AD) develops differently from person to person, many common symptoms exist.
- November 5, 2012 | BY
Samantha Budd, project leader for AstraZeneca’s Alzheimer’s program, discusses the challenges the biopharmaceutical industry faces with this neurodegenerative disease.
- October 22, 2012 | BY
Patient-derived xenografts, otherwise referred to as animal avatars, preserve the original characteristics of a patient’s cancer and have been shown to mimic the disease more effectively than deriving tumors from cancer cell lines.
- October 16, 2012 | BY
The search for Ehrlich’s Magic Bullet took a huge leap when someone asked, “Why not antibodies?”
- October 8, 2012 | BY
Once an experimental curiosity, pharmaceutical companies are embracing the 6-month transgenic mouse carcinogenicity study as an alternative to the 2-year mouse carcinogenicity bioassay. Here’s why.
- October 1, 2012 | BY
Each year in the US, approximately 3,000 children are diagnosed with leukemia, the most common childhood cancer. This cancer of the blood makes up one-third of cancer cases in children and is the leading cause of death in children up to age 14. Acute lymphoblastic leukemia (ALL) is the most common form of leukemia in ...
- September 24, 2012 | BY
Two broad types of cancer vaccines exist: preventive cancer vaccines, which target infectious agents causing cancer development, and therapeutic vaccines, which treat an existing cancer by strengthening the body’s natural defense.
- September 21, 2012 | BY
A highly publicized event perpetuated myths of harm from the MMR vaccine.
- September 20, 2012 | BY
I’m part of the generation who vividly remembers mumps’ high fever and the itching from chicken pox.